News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (ALIOF.PK) CEO Says Macitentan Has 'Very High' Chances of Success



1/11/2012 8:50:45 AM

Actelion Ltd.’s experimental drug macitentan has a “very high” probability of success in a clinical trial that will be critical for the company’s future, Chief Executive Officer Jean-Paul Clozel said. Data from a late-stage trial of the medicine, a successor to Actelion’s top-selling lung drug Tracleer, will “realistically” be released in the second quarter, Clozel said in an interview yesterday in San Francisco. “What is important for us is to do everything in order for the trial to succeed,” such as monitoring the quality of data collection, Clozel said. “We are working on making this thing work.”

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES